TY - JOUR
T1 - British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
AU - Sundar, Sudha
AU - Manchanda, Ranjit
AU - Gourley, Charlie
AU - George, Angela
AU - Wallace, Andrew
AU - Balega, Janos
AU - Williams, Sarah
AU - Wallis, Yvonne
AU - Edmondson, Richard
AU - Nicum, Shibani
AU - Frost, Jonathan
AU - Attygalle, Ayoma
AU - Fotopoulou, Christina
AU - Bowen, Rebecca
AU - Bell, Dani
AU - Gajjar, Ketankumar
AU - Ramsay, Bruce
AU - Wood, Nicholas J
AU - Ghaem-Maghami, Sadaf
AU - Miles, Tracie
AU - Ganesan, Raji
N1 - © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.
AB - The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript.
KW - BRCA1 protein
KW - BRCA2 protein
KW - fallopian tube neoplasms
KW - ovarian neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85099803630&partnerID=8YFLogxK
U2 - 10.1136/ijgc-2020-002112
DO - 10.1136/ijgc-2020-002112
M3 - Review article
C2 - 33468564
SN - 1525-1438
VL - 31
SP - 272
EP - 278
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 2
ER -